☰

Margalit B. Mokyr - Publications

Affiliations: 
University of Illinois at Chicago, Health Sciences Center 
Area:
Biochemistry, Immunology, Molecular Biology, Oncology
Tree Info Similar researchers PubMed Report error

19 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2008 Stoyanova T, Yoon T, Kopanja D, Mokyr MB, Raychaudhuri P. The xeroderma pigmentosum group E gene product DDB2 activates nucleotide excision repair by regulating the level of p21Waf1/Cip1. Molecular and Cellular Biology. 28: 177-87. PMID 17967871 DOI: 10.1128/MCB.00880-07  0.56
2006 Mokyr MB, Place AT, Artwohl JE, Valli VE. Importance of signaling via the IFN-alpha/beta receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor. Cancer Immunology, Immunotherapy : Cii. 55: 459-68. PMID 15965646 DOI: 10.1007/s00262-005-0029-2  0.56
2004 Jovasevic VM, Gorelik L, Bluestone JA, Mokyr MB. Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity. Journal of Immunology (Baltimore, Md. : 1950). 172: 1449-54. PMID 14734721  1
2003 Donepudi M, Jovasevic VM, Raychaudhuri P, Mokyr MB. Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells. Cancer Immunology, Immunotherapy : Cii. 52: 162-70. PMID 12649745 DOI: 10.1007/s00262-002-0345-8  0.56
2002 Sojka DK, Felnerova D, Mokyr MB. Anti-metastatic activity of hapten-modified autologous tumor cell vaccine in an animal tumor model. Cancer Immunology, Immunotherapy : Cii. 51: 200-8. PMID 12012107 DOI: 10.1007/s00262-002-0271-9  0.56
2001 Jovasevic VM, Mokyr MB. Melphalan-induced expression of IFN-beta in MOPC-315 tumor-bearing mice and its importance for the up-regulation of TNF-alpha expression. Journal of Immunology (Baltimore, Md. : 1950). 167: 4895-901. PMID 11673494 DOI: 10.4049/JIMMUNOL.167.9.4895  1
2001 Donepudi M, Raychaudhuri P, Bluestone JA, Mokyr MB. Mechanism of melphalan-induced B7-1 gene expression in P815 tumor cells. Journal of Immunology (Baltimore, Md. : 1950). 166: 6491-9. PMID 11359799  0.56
2000 Sojka DK, Donepudi M, Bluestone JA, Mokyr MB. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. Journal of Immunology (Baltimore, Md. : 1950). 164: 6230-6. PMID 10843675  1
2000 Sojka DK, La Motte RN, Mokyr MB. B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells. Cancer Immunology, Immunotherapy : Cii. 49: 10-22. PMID 10782862  0.56
1999 Donepudi M, Quach DD, Mokyr MB. Signaling through CD40 enhances cytotoxic T lymphocyte generation by CD8+ T cells from mice bearing large tumors. Cancer Immunology, Immunotherapy : Cii. 48: 153-64. PMID 10414470  1
1999 La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism. Journal of Immunology (Baltimore, Md. : 1950). 162: 4817-23. PMID 10202025  0.56
1998 La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells. Journal of Immunology (Baltimore, Md. : 1950). 161: 6552-8. PMID 9862681  0.56
1996 La Motte RN, Rubin MA, Barr E, Leiden JM, Bluestone JA, Mokyr MB. Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. Cancer Immunology, Immunotherapy : Cii. 42: 161-9. PMID 8640844 DOI: 10.1007/s002620050266  0.56
1995 Cook-Mills JM, Mokyr MB, Cohen RL, Perlman RL, Chambers DA. Neurotransmitter suppression of the in vitro generation of a cytotoxic T lymphocyte response against the syngeneic MOPC-315 plasmacytoma. Cancer Immunology, Immunotherapy : Cii. 40: 79-87. PMID 7882386 DOI: 10.1007/BF01520288  0.56
1993 Laude M, Russo KL, Mokyr MB, Dray S. Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy Cancer Immunology Immunotherapy. 36: 229-236. PMID 8439986 DOI: 10.1007/BF01740904  0.56
1993 Laude M, Russo KL, Mokyr MB, Dray S. Two tumor models of curative adoptive chemoimmunotherapy using tumor-infiltrated spleen cells with potent antitumor cytotoxicity stimulated by antigen-sharing tumors Cancer Immunology Immunotherapy. 37: 89-96. PMID 8319246 DOI: 10.1007/BF01517040  0.56
1988 Wise JA, Mokyr MB, Dray S. Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas. Cancer Immunology, Immunotherapy : Cii. 27: 191-7. PMID 3263205 DOI: 10.1007/BF00205439  0.56
1985 Mokyr MB, Colvin M, Dray S. Cyclophosphamide-mediated enhancement of antitumor immune potential of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor International Journal of Immunopharmacology. 7: 111-122. PMID 3922904 DOI: 10.1016/0192-0561(85)90016-5  0.56
1984 Ye QW, Mokyr MB, Pyle JM, Dray S. Suppression of antitumor immunity by macrophages in spleens of mice bearing a large MOPC-315 tumor Cancer Immunology Immunotherapy. 16: 162-169. PMID 6561068 DOI: 10.1007/BF00205423  0.56
Show low-probability matches.